Develops cell therapies for oncology, focusing on chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies.
Legend Biotech Corporation, a clinical-stage biopharmaceutical firm and subsidiary of Genscript Biotech Corporation, is dedicated to pioneering novel cell therapies for oncology and other critical medical indications across the globe, including the United States and China. At the forefront of its development efforts is LCAR-B38M, a promising chimeric antigen receptor therapy designed specifically for the treatment of multiple myeloma (MM). This innovative therapy is undergoing clinical trials, including comparisons with standard triplet therapy in revlimid-refractory multiple myeloma patients.
In addition to LCAR-B38M, Legend Biotech boasts a robust pipeline of early-stage autologous cell therapy candidates currently in Phase I clinical trials. These candidates aim to address conditions such as gastric cancer and T cell lymphoma. The company is also advancing CAR-T cell therapies targeting CD20, CD22, and CD19 for non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia, respectively. Moreover, Legend Biotech is actively pursuing preclinical and clinical development programs for the treatment of solid tumors and infectious diseases.
Founded in 2014 and headquartered in Somerset, New Jersey, Legend Biotech Corporation collaborates closely with industry leaders such as Janssen Biotech, Inc. Through strategic partnerships and licensing agreements, the company aims to accelerate the development and commercialization of its innovative therapies, driving forward advancements in cellular medicine to benefit patients worl dwide.